HCW Biologics Deal History & Licensing Activity
HCW Biologics is a biotech. Over the past three years, HCW Biologics has been involved in 3 licensing and acquisition transactions, with a primary focus on Peptides (2 deals). The company currently has 1 active clinical trial, primarily in Other.
Deals (12mo)
2
Active Trials
1
Top Modality
Peptides
Focus Area
Other
HCW Biologics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving HCW Biologics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HCW11-006 | Akron Biotech | Peptides | Preclinical | license | Sep 8, 2026 |
| HCW9206 and HCW9201 | Wugen | Cell Therapy | Preclinical | option | May 27, 2026 |
HCW Biologics Pipeline Focus
Therapeutic areas and modalities where HCW Biologics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
HCW Biologics Clinical Pipeline
HCW Biologics has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches HCW Biologics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About HCW Biologics Licensing & Deal Activity
HCW Biologics is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, HCW Biologics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for HCW Biologics include Other (5 deals and trials), and Autoimmune (1 deal and trial). In terms of modality, HCW Biologics has shown particular interest in peptides, cell therapy, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for HCW Biologics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against HCW Biologics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.